Effectiveness of a Nurse Practitioner-Led Collaborative Healthcare Model in Reducing Anxiety and Depression and Improving Quality of Life in Patients With Heart Failure: A Randomized Controlled Trial.

J Cardiovasc NursOct 28, 2025 (epub)
Clinical ResearchCardiologyPsychiatry

Chih-Wen Chen, Tsae-Jyy Wang, Chieh-Yu Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated a nurse practitioner-led collaborative healthcare model for anxiety, depression, and quality of life among 100 patients with heart failure at a regional teaching hospital in southern Taiwan. Participants were assigned to standard care or a 12-week intervention. The intervention group had significant reductions in anxiety and depressive symptoms and improvements in quality of life. Compared with standard care, improvement in the intervention group was sustained at weeks 12, 16, and 20. The abstract does not report effect sizes or specific outcome scores.

Key findings

  • The 12-week intervention was associated with significant reductions in anxiety and depressive symptoms.
  • Quality of life improved in the intervention group.
  • Compared with standard care, improvement showed a sustained trend at weeks 12, 16, and 20.

Why it matters

Heart failure care may need to address psychological symptoms alongside physical health. This trial suggests that a collaborative model led by a nurse practitioner can improve anxiety, depression, and quality of life compared with standard care, highlighting a potential way to integrate these concerns into care. The abstract provides no effect sizes, so the magnitude of benefit cannot be assessed.

What to keep in mind

The trial was conducted at one regional teaching hospital in southern Taiwan, and the abstract does not report effect sizes or detailed outcome measures.

Source

Published in J Cardiovasc Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.